DRREDDY Stock Overview
Operates as an integrated pharmaceutical company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,195.60 |
| 52 Week High | ₹1,421.49 |
| 52 Week Low | ₹1,020.00 |
| Beta | 0.34 |
| 1 Month Change | 7.76% |
| 3 Month Change | -1.17% |
| 1 Year Change | 1.18% |
| 3 Year Change | 53.74% |
| 5 Year Change | 62.48% |
| Change since IPO | 1,241.49% |
Recent News & Updates
The Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Yearly Results Are Out And Analysts Have Published New Forecasts
May 13
Is Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Trading At A 20% Discount?
Apr 10Recent updates
The Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Yearly Results Are Out And Analysts Have Published New Forecasts
May 13Is Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Trading At A 20% Discount?
Apr 10Does Dr. Reddy's Laboratories (NSE:DRREDDY) Have A Healthy Balance Sheet?
Mar 02Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Prospects Need A Boost To Lift Shares
Feb 12With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
Dec 27Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?
Nov 23Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Shareholder Returns
| DRREDDY | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.1% | -2.4% | -1.6% |
| 1Y | 1.2% | 12.4% | 1.7% |
Return vs Industry: DRREDDY underperformed the Indian Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: DRREDDY matched the Indian Market which returned 1.7% over the past year.
Price Volatility
| DRREDDY volatility | |
|---|---|
| DRREDDY Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: DRREDDY has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: DRREDDY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 27,048 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| DRREDDY fundamental statistics | |
|---|---|
| Market cap | ₹995.91b |
| Earnings (TTM) | ₹56.54b |
| Revenue (TTM) | ₹325.54b |
17.6x
P/E Ratio3.1x
P/S RatioIs DRREDDY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRREDDY income statement (TTM) | |
|---|---|
| Revenue | ₹325.54b |
| Cost of Revenue | ₹135.11b |
| Gross Profit | ₹190.43b |
| Other Expenses | ₹133.88b |
| Earnings | ₹56.54b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 67.87 |
| Gross Margin | 58.50% |
| Net Profit Margin | 17.37% |
| Debt/Equity Ratio | 13.6% |
How did DRREDDY perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield12%
Payout RatioDoes DRREDDY pay a reliable dividends?
See DRREDDY dividend history and benchmarks| Dr. Reddy's Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Jul 10 2025 |
| Dividend Pay Date | Aug 23 2025 |
| Days until Ex dividend | 58 days |
| Days until Dividend pay date | 102 days |
Does DRREDDY pay a reliable dividends?
See DRREDDY dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 23:56 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 77 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |